Denali Therapeutics Inc (NASDAQ:DNLI)

30.93
Delayed Data
As of Jun 24
 +0.74 / +2.45%
Today’s Change
20.24
Today|||52-Week Range
79.70
-30.65%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$3.8B

Company Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Contact Information

Denali Therapeutics, Inc.
161 Oyster Point Boulevard
San Francisco California 94080
P:(615) 866-8548
Investor Relations:

Employees

Shareholders

Individual stakeholders51.15%
Mutual fund holders41.16%
Other institutional27.67%

Top Executives

Ryan J. WattsPresident, Chief Executive Officer & Director
Alexander O. SchuthSecretary, Chief Operating & Financial Officer
Carole HoChief Medical Officer & Head-Development
Dana AndersenCTO & Chief Manufacturing Officer
Joe LewcockChief Scientific Officer